![](https://tracker.live.rns-distribution.com/track.live-rns/4965256_75d1671758db0ed18eba2dbba83793b2.png)
Maven Income and Growth VCT 5 PLC (the Company)
Result of General Meeting - 9 November 2023
This Announcement is made by the Company in connection with the offer for subscription (Offer) of new ordinary shares of 10p each in the capital of the Company (New Shares).
The Board is pleased to announce that, at the General Meeting of the Company held on 9 November 2023, the resolutions proposed, as set out in the Notice of General Meeting in the Circular to Shareholders dated 13 October 2023, were duly passed as follows:
Resolution 1 - to authorise the Directors to allot New Shares; and
Resolution 2 - to authorise the disapplication of pre-emption rights.
At the record date for the General Meeting, being 7 November 2023, the total number of voting rights in the Company stood at 195,795,711 and the total number of ordinary shares in issue was 195,795,711.
The Company advises that, for the General Meeting, valid proxy appointments were made in respect of
7,630,104 ordinary shares and that the number of proxy votes lodged for each Resolution were as follows:
Resolution | For | Discretion | Against | Withheld | Total |
1 | 7,259,694 | 124,915 | 245,495 | 0 | 7,630,104 |
2 | 7,031,106 | 190,566 | 378,503 | 29,929 | 7,630,104 |
A vote withheld is not a vote in law and any such votes have not been included in the votes for or against the respective Resolutions.
Passing of Resolutions
A copy of the Resolutions passed at the General Meeting held on 9 November 2023 has been submitted to the National Storage Mechanism and will shortly be available for inspection at:
https://www.fca.org.uk/markets/primary-markets/regulatory-disclosures/national-storage-mechanism
Issued on behalf of the Board
Maven Capital Partners UK LLP
Secretary
9 November 2023
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.